Cargando…

Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic‐associated molecular subtypes and genomic mutations

Objective: Due to a lack of effective therapy, triple-negative breast cancer (TNBC) is extremely poor prognosis. Metabolic reprogramming is an important hallmark in tumorigenesis, cancer diagnosis, prognosis, and treatment. Categorizing metabolic patterns in TNBC is critical to combat heterogeneity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lijuan, Wu, Nan, Zhuang, Gaojian, Geng, Lin, Zeng, Yu, Wang, Xuan, Wang, Shuang, Ruan, Xianhui, Zheng, Xiangqian, Liu, Juntian, Gao, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502304/ https://www.ncbi.nlm.nih.gov/pubmed/37719859 http://dx.doi.org/10.3389/fphar.2023.1224828

Ejemplares similares

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
por: Liu, Cun, et al.
Publicado: (2019)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Zhang, Yubao, et al.
Publicado: (2021)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

Identification and validation of eight estrogen-related genes for predicting prognosis of papillary thyroid cancer
por: Zeng, Yu, et al.
Publicado: (2023)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)

Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning
por: Tang, Lijuan, et al.
Publicado: (2023)

Induced Cell Cycle Arrest in Triple-Negative Breast Cancer by Combined Treatment of Itraconazole and Rapamycin
por: Wu, Hua-Tao, et al.
Publicado: (2022)

SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer
por: Liu, Peng, et al.
Publicado: (2018)

Editorial: Targeting triple negative breast cancer by natural compounds
por: Kumar, Shashank, et al.
Publicado: (2023)

Sanguisorba officinalis L. Suppresses Triple-Negative Breast Cancer Metastasis by Inhibiting Late-Phase Autophagy via Hif-1α/Caveolin-1 Signaling
por: Wang, Neng, et al.
Publicado: (2020)

Current landscape of personalized clinical treatments for triple-negative breast cancer
por: Zhang, Jun, et al.
Publicado: (2022)

Immunoadjuvant Nanoparticles as Trojan Horses for Enhanced Photo-Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wu, Jinxian, et al.
Publicado: (2022)

Corrigendum: Sanguisorba officinalis L. Suppresses Triple-Negative Breast Cancer Metastasis by Inhibiting Late-Phase Autophagy via Hif-1α/Caveolin-1 Signaling
por: Wang, Neng, et al.
Publicado: (2022)

Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway
por: Yang, Ting, et al.
Publicado: (2021)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates
por: Lastraioli, Elena
Publicado: (2020)

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line
por: Chamaraux-Tran, Thiên-Nga, et al.
Publicado: (2022)

Palmatine Attenuates Metastatic Lung Colonization of Triple Negative Breast Cancer Cells
por: Ativui, Selase, et al.
Publicado: (2022)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
por: Wu, Nan, et al.
Publicado: (2018)

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
por: Chen, Haixia, et al.
Publicado: (2018)

Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
por: Zhao, Wenjie, et al.
Publicado: (2021)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Dandelion extract inhibits triple-negative breast cancer cell proliferation by interfering with glycerophospholipids and unsaturated fatty acids metabolism
por: Wang, Shan, et al.
Publicado: (2022)

Cinobufacini Injection Inhibits the Proliferation of Triple-Negative Breast Cancer Through the Pin1–TAZ Signaling Pathway
por: Kong, Lu, et al.
Publicado: (2022)

Role of microRNA/lncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer
por: Hu, Xue, et al.
Publicado: (2022)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Bioluminescence Imaging-Based Assessment of the Anti-Triple-Negative Breast Cancer and NF-Kappa B Pathway Inhibition Activity of Britanin
por: Xu, Xinyi, et al.
Publicado: (2020)

CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis
por: Li, Xiaoli, et al.
Publicado: (2020)

Ethanol Extract of Brucea javanica Seed Inhibit Triple-Negative Breast Cancer by Restraining Autophagy via PI3K/Akt/mTOR Pathway
por: Chen, Xiaohong, et al.
Publicado: (2020)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Molecular stratification within triple-negative breast cancer subtypes
por: Wang, Dong-Yu, et al.
Publicado: (2019)

New insight into ischemic stroke: Circadian rhythm in post-stroke angiogenesis
por: Zhang, Yuxing, et al.
Publicado: (2022)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022)

Dezocine, An Opioid Analgesic, Exerts Antitumor Effects in Triple-Negative Breast Cancer by Targeting Nicotinamide Phosphoribosyltransferase
por: Xue, Chenyang, et al.
Publicado: (2021)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression
por: Peng, Fu, et al.
Publicado: (2022)

Exploring the Regulation Mechanism of Xihuang Pill, Olibanum and β-Boswellic Acid on the Biomolecular Network of Triple-Negative Breast Cancer Based on Transcriptomics and Chemical Informatics Methodology
por: Yang, Kailin, et al.
Publicado: (2020)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients
por: Zhang, Biao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e90kqq0b68scrnck301n2o6i4g